000			02068 a2200589 4500
005			20250517164149.0
264		0	_c20170925
008			201709s 0 0 eng d
022			_a1474-5488
024	7		_a10.1016/S1470-2045(17)30446-1 _2doi
040			_aNLM _beng _cNLM
100	1		_aMaio, Michele
245	0	0	_aTremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. _h[electronic resource]
260			_bThe Lancet. Oncology _c09 2017
300			_a1261-1273 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
650	0	4	_aAged
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aDisease-Free Survival
650	0	4	_aDouble-Blind Method
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMesothelioma _xdrug therapy
650	0	4	_aMesothelioma, Malignant
650	0	4	_aMiddle Aged
650	0	4	_aResponse Evaluation Criteria in Solid Tumors
650	0	4	_aSurvival Rate
650	0	4	_aTreatment Outcome
700	1		_aScherpereel, Arnaud
700	1		_aCalabrò, Luana
700	1		_aAerts, Joachim
700	1		_aPerez, Susana Cedres
700	1		_aBearz, Alessandra
700	1		_aNackaerts, Kristiaan
700	1		_aFennell, Dean A
700	1		_aKowalski, Dariusz
700	1		_aTsao, Anne S
700	1		_aTaylor, Paul
700	1		_aGrosso, Federica
700	1		_aAntonia, Scott J
700	1		_aNowak, Anna K
700	1		_aTaboada, Maria
700	1		_aPuglisi, Martina
700	1		_aStockman, Paul K
700	1		_aKindler, Hedy L
773	0		_tThe Lancet. Oncology _gvol. 18 _gno. 9 _gp. 1261-1273
856	4	0	_uhttps://doi.org/10.1016/S1470-2045(17)30446-1 _zAvailable from publisher's website
999			_c27388361 _d27388361